Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.

Company profile
Ticker
PALI
Exchange
Website
CEO
Kenneth Carter
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
Former names
Neuralstem, Inc., Seneca Biopharma, Inc.
SEC CIK
Corporate docs
Subsidiaries
Leading Biosciences, Inc. • Suzhou Neuralstem Biopharmaceutical Co., Ltd. ...
IRS number
522007292
PALI stock data
Latest filings (excl ownership)
8-K
Other Events
13 Mar 23
8-K
Mr. McRae is an industry veteran with a proven track record of operational, clinical, and strategic business development execution
8 Feb 23
EFFECT
Notice of effectiveness
25 Jan 23
424B3
Prospectus supplement
24 Jan 23
CORRESP
Correspondence with SEC
20 Jan 23
UPLOAD
Letter from SEC
19 Jan 23
D
$2.50 mm in options / securities to be acquired, sold $2.50 mm, 6 investors
18 Jan 23
S-1
IPO registration
13 Jan 23
8-K
Entry into a Material Definitive Agreement
4 Jan 23
424B5
Prospectus supplement for primary offering
4 Jan 23
Latest ownership filings
3
Robert Curtis McRae
15 Feb 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
Altium Capital Management LP
14 Feb 23
SC 13G/A
Lind Global Fund II LP
13 Feb 23
4
John David Finley
8 Feb 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
4
John David Finley
6 Jan 23
4
John David Finley
2 Sep 22
4
John David Finley
25 Aug 22
SC 13G
INTRACOASTAL CAPITAL, LLC
22 Aug 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.01 mm | 14.01 mm | 14.01 mm | 14.01 mm | 14.01 mm | 14.01 mm |
Cash burn (monthly) | (no burn) | 9.92 k | 1.47 mm | 1.33 mm | 1.01 mm | 1.09 mm |
Cash used (since last report) | n/a | 56.45 k | 8.37 mm | 7.54 mm | 5.77 mm | 6.22 mm |
Cash remaining | n/a | 13.95 mm | 5.64 mm | 6.47 mm | 8.24 mm | 7.79 mm |
Runway (months of cash) | n/a | 1407.2 | 3.8 | 4.9 | 8.1 | 7.1 |
Institutional ownership, Q4 2022
6.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 16 |
Opened positions | 3 |
Closed positions | 22 |
Increased positions | 0 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 541.64 mm |
Total shares | 2.82 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Regional Medical Center Yuma | 2.25 mm | $5.55 mm |
Armistice Capital | 281.05 k | $0.00 |
Intracoastal Capital | 131.09 k | $0.00 |
CVI | 40.00 k | $208.00 mm |
Lind Global Fund II | 30.99 k | $0.00 |
Warberg Asset Management | 26.32 k | $136.84 mm |
Virtu Financial | 20.46 k | $106.00 k |
Two Sigma Securities | 19.69 k | $102.40 mm |
Two Sigma Investments | 10.40 k | $54.06 mm |
UBS UBS Group AG - Registered Shares | 4.12 k | $21.40 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Feb 23 | John David Finley | Common Stock | Grant | Acquire A | No | No | 2.4 | 57,200 | 137.28 k | 57,200 |
6 Feb 23 | John David Finley | Common Stock | Grant | Acquire A | No | No | 0 | 32,500 | 0.00 | 32,500 |
6 Feb 23 | John David Finley | Common Stock | Grant | Acquire A | No | No | 0 | 41,700 | 0.00 | 41,700 |
3 Jan 23 | John David Finley | Common Stock | Grant | Acquire A | No | No | 0 | 5,236 | 0.00 | 5,236 |
1 Sep 22 | John David Finley | Common Stock, par value $0.01 | Buy | Acquire P | No | No | 0.1437 | 19,481.242 | 2.80 k | 148,727.242 |
23 Aug 22 | John David Finley | Common Stock, par value $0.01 | Buy | Acquire P | No | No | 0.16 | 7,350 | 1.18 k | 129,246 |
News
5 Value Stocks In The Healthcare Sector
20 Mar 23
Palisade Bio Promotes Robert McRae to Chief Operating Officer
8 Feb 23
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
31 Jan 23
12 Health Care Stocks Moving In Tuesday's Intraday Session
31 Jan 23
A Look Into Healthcare Sector Value Stocks
23 Jan 23
Press releases
PALISADES ANNOUNCES NEW FOUND'S INCREASED WEIGHTING BY GDXJ
15 Mar 23
Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent
1 Mar 23
Palisade Bio Promotes Robert McRae to Chief Operating Officer
8 Feb 23
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
11 Jan 23
Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million
10 Jan 23